Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents

Seminars in Oncology
Jane Pruemer

Abstract

The risk of cancer-associated thrombosis can be substantial, depending on tumor type, extent of cancer, and type of treatment. Unfractionated heparin and warfarin have been used in the prevention of cancer-associated thrombosis, but low-molecular-weight heparin (LMWH) is widely used for the prevention of venous thromboembolism in high-risk patients. Long-term management with warfarin is associated with close monitoring, an increased risk of drug interactions, and bleeding. LMWHs may offer an alternative outpatient treatment strategy for prophylactic treatment because of their simpler dosing, more predictable anticoagulant activity, and improved safety profile. Clinical trials examining the treatment of venous thromboembolism with LMWH in patients with cancer suggest a survival advantage for the treated groups. Subtle differences in the pharmacokinetics of available LMWHs exist, and each LMWH should be regarded as a distinct drug. Pharmacists should be aware of the US Food and Drug Administration-approved uses for each LMWH, dosing options, and the advantages and disadvantages of available delivery systems for various patient populations. Pharmacists can play a major role in educating patients and other health care professionals...Continue Reading

References

Oct 1, 1976·Carbohydrate Research·E A Johnson, B Mulloy
Mar 22, 1976·Biochemical and Biophysical Research Communications·L H LamR D Rosenberg
Oct 1, 1987·Seminars in Thrombosis and Hemostasis·J J CastellotM J Karnovsky
Dec 1, 1988·American Journal of Hematology·J Harenberg, D L Heene
Aug 15, 1986·Thrombosis Research·F FernandezM R Buchanan
Jan 1, 1971·Scandinavian Journal of Haematology·C Eika
Oct 16, 1980·Biochemical and Biophysical Research Communications·R D RosenbergW T Gardner
Sep 1, 1994·The Journal of Clinical Investigation·Y ZhangP P Nawroth
Mar 27, 1995·Archives of Internal Medicine·A W LensingJ Hirsh
Dec 1, 1993·Journal of Clinical Pathology·R Nounou, D Spence
Oct 13, 1993·JAMA : the Journal of the American Medical Association·S L Nightingale
Jan 1, 1996·Journal of Cancer Research and Clinical Oncology·E HeinmöllerH Zirngibl
Apr 1, 1997·Thrombosis and Haemostasis·B MulloyT W Barrowcliffe
Sep 4, 1997·The New England Journal of Medicine·J I Weitz
Apr 21, 1999·Lancet·F R Rosendaal
Sep 1, 1999·The American Journal of Cardiology·J M SpandorferG J Merli
Feb 17, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Ben-AmG Burke
Feb 19, 2000·Clinical Cardiology·A G Turpie
Apr 5, 2000·PharmacoEconomics·W E WadeM Perri

❮ Previous
Next ❯

Citations

Aug 29, 2007·Oncology Nursing Forum·Nancy Eisenson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.